before medical reports of CagriSema uncovered that it helped sufferers attain noticeably higher weight loss than semaglutide (Wegovy) did. whether or not Lilly's Zepbound/Mounjaro topples Wegovy, it's feasible that CagriSema could enter the industry at the best time for Novo Nordisk to keep its Over-all Management in the weight problems drug market